Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22040181 | 1.00 | NISCH (0.41) | NISCHPTGS2GRM2HTR2APTGS1 | |
| SCHEMBL22039488 | 0.85 | CYP11B2 (0.36) | PTGS2GRM2PTGS1TAS1R3TAS1R1 | |
| SCHEMBL23878330 | 0.85 | CYP11B2 (0.36) | PTGS2GRM2PTGS1TAS1R3TAS1R1 | |
| SCHEMBL28714501 | 0.80 | NISCH (0.39) | NISCHADRA2AADRA2B | |
| SCHEMBL20835774 | 0.77 | KMO (0.43) | NISCHPTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL22040133 | 0.76 | NOS3 (0.38) | PTGS2PTGS1 | |
| SCHEMBL22040850 | 0.76 | NOS3 (0.38) | PTGS2PTGS1 | |
| SCHEMBL22039704 | 0.76 | NOS3 (0.38) | PTGS2PTGS1 | |
| SCHEMBL22040809 | 0.75 | NOS3 (0.36) | NISCH | |
| SCHEMBL23878350 | 0.75 | NOS3 (0.36) | NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889138-B1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| CN-111217802-B | Histone acetylase p300 inhibitor and application thereof | 海创药业股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3889138-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020108500-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | 成都海创药业有限公司 | 2020-06-04 | — | — | WO | disclosed |
| CN-111217802-A | Histone acetylase p300 inhibitor and application thereof | 成都海创药业有限公司 | 2020-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | NISCH 3899/4885PTGS2 3609/4885GRM2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.